|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
7/14/2011 8:32:53 AM
Last year, Merck disclosed plans to save up to $3.5 billion by closing numerous research sites and manufacturing plants, and eliminate roughly 15,000 jobs by 2012, or roughly 10 percent of the total headcount that included the thousands of people who were part of the 2009 acquisition of Schering-Plough. Before the deal, Merck employed about 53,000 people (read this). By March, Merck managed to get the the headcount down to roughly 93,000 (see here), which means another 8,000 or so jobs must still go. And sources say the layoff process is expected to accelerate shortly - most likely in early August - as the drugmaker continues its restructuring plan and looks for additional ways to save money.
|
|
|
|
|
|
|
|
|
|
|